SG11202011597RA - Heavy chain antibodies binding to cd19 - Google Patents

Heavy chain antibodies binding to cd19

Info

Publication number
SG11202011597RA
SG11202011597RA SG11202011597RA SG11202011597RA SG11202011597RA SG 11202011597R A SG11202011597R A SG 11202011597RA SG 11202011597R A SG11202011597R A SG 11202011597RA SG 11202011597R A SG11202011597R A SG 11202011597RA SG 11202011597R A SG11202011597R A SG 11202011597RA
Authority
SG
Singapore
Prior art keywords
heavy chain
chain antibodies
antibodies binding
binding
heavy
Prior art date
Application number
SG11202011597RA
Inventor
Shelley Force Aldred
Schooten Wim Van
Katherine Harris
Udaya Rangaswamy
Nathan Trinklein
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of SG11202011597RA publication Critical patent/SG11202011597RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202011597RA 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19 SG11202011597RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701281P 2018-07-20 2018-07-20
PCT/US2019/042633 WO2020018922A1 (en) 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19

Publications (1)

Publication Number Publication Date
SG11202011597RA true SG11202011597RA (en) 2020-12-30

Family

ID=67515196

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011597RA SG11202011597RA (en) 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19

Country Status (12)

Country Link
US (1) US20210332133A1 (en)
EP (1) EP3823990A1 (en)
JP (1) JP7439046B2 (en)
KR (1) KR20210032311A (en)
CN (2) CN116769032A (en)
AU (1) AU2019305663A1 (en)
BR (1) BR112020024074A2 (en)
CA (1) CA3101069A1 (en)
IL (1) IL279010A (en)
MX (1) MX2021000708A (en)
SG (1) SG11202011597RA (en)
WO (1) WO2020018922A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190053835A (en) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 CD3 binding antibody
KR102505681B1 (en) 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 CD3 binding antibody
BR112019026907A2 (en) 2017-06-20 2020-06-30 Teneobio, Inc. ANTIBODIES ONLY OF HEAVY CHAIN ANTI-BCMA, POLYNUCLEOTIDE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, ITS USES AND METHOD TO PRODUCE THE SAME
CN117567624A (en) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 Heavy chain-only anti-BCMA antibodies
CN111683966B (en) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 Heavy chain antibodies that bind CD22
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
PE20230431A1 (en) 2020-04-29 2023-03-08 Teneobio Inc MULTI-SPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
IL299867A (en) * 2020-07-16 2023-03-01 Nanjing Legend Biotech Co Ltd Cd19 binding molecules and uses thereof
JP2023542257A (en) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド Method of administering therapeutic doses of bispecific T cell inducing molecules for the treatment of cancer
BR112023020450A2 (en) * 2021-04-06 2024-01-23 Teneobio Inc ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (en) 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
PT2311874T (en) 2004-07-22 2017-08-25 Univ Erasmus Med Ct Rotterdam Binding molecules
PL1853718T3 (en) * 2005-02-15 2016-01-29 Univ Duke Anti-cd19 antibodies and uses in oncology
CN101218351A (en) * 2005-02-15 2008-07-09 杜克大学 Anti-CD19 antibodies and uses in oncology
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
DK2315780T3 (en) * 2008-07-17 2015-10-19 Novartis Ag Compositions and methods for the use of therapeutic antibodies
JP6061469B2 (en) 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Anti-BCMA antibody
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP3197917B1 (en) * 2014-09-26 2022-10-12 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
CN105384825B (en) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
KR20190053835A (en) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 CD3 binding antibody
CA3034706A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
KR102505681B1 (en) 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 CD3 binding antibody

Also Published As

Publication number Publication date
CN116769032A (en) 2023-09-19
MX2021000708A (en) 2021-03-25
AU2019305663A1 (en) 2021-03-11
CN112351997A (en) 2021-02-09
JP7439046B2 (en) 2024-02-27
US20210332133A1 (en) 2021-10-28
BR112020024074A2 (en) 2021-02-17
KR20210032311A (en) 2021-03-24
JP2021530236A (en) 2021-11-11
WO2020018922A1 (en) 2020-01-23
CA3101069A1 (en) 2020-01-23
EP3823990A1 (en) 2021-05-26
IL279010A (en) 2021-01-31
CN112351997B (en) 2023-05-26

Similar Documents

Publication Publication Date Title
IL279010A (en) Heavy chain antibodies binding to cd19
IL276537A (en) Antibodies binding to gprc5d
IL283939A (en) Antibodies binding to cd3
IL287613A (en) Antibodies binding to gprc5d
IL286398A (en) Heavy chain antibodies binding to psma
ZA202203250B (en) Cd3 binding antibodies
IL263840A (en) Cd3 binding antibodies
IL263083A (en) Single chain variable fragment cd3 binding proteins
IL274370A (en) Single domain antibodies that bind to cd137
IL282590A (en) Heavy chain antibodies binding to cd38
IL275498A (en) Heavy chain antibodies binding to cd22
IL279894A (en) Antibodies binding to ilt4
HK1256300A1 (en) Antibodies that specifically bind to tl1a
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL288749A (en) Multispecific heavy chain antibodies binding to cd22 and cd3
IL273235A (en) Heavy chain antibodies binding to ectoenzymes
IL269394A (en) Antibodies binding to steap-1
HK1253947A1 (en) Heavy chain only antibodies to ang-2
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
SG11202106990PA (en) BISPECIFIC ANTIBODY BINDING TO TfR
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies
GB201715149D0 (en) IL-ß binding antibody
GB201718734D0 (en) Single domain antibodies that bind to CD137